Drug intelligence / Profile preview

azacitidine + entinostat + nivolumab

Development stage: Unknown
Lead developer: Sidney Kimmel Comprehensive Cancer Center
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous, Oral, Intravenous

Overview

A combination therapy consisting of the DNA methyltransferase inhibitor azacitidine, the histone deacetylase inhibitor entinostat, and the PD-1 immune checkpoint inhibitor nivolumab. This regimen combines epigenetic therapy with immunotherapy and is being investigated primarily for non-small cell lung cancer (NSCLC) and other solid tumors. The combination is administered in a specific schedule: azacitidine 40mg/m² on days 1-5 and 8-10, entinostat 5mg on days 3 and 10, and nivolumab 3mg/kg on days 1 and 15 of a 28-day cycle for 6 cycles, followed by nivolumab monotherapy until disease progression.

Targets

HDAC (HDAC family)PDCD1 (Programmed cell death protein 1 receptor)DNMT (DNA methyltransferase)

Beyond the preview

Go deeper on azacitidine + entinostat + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azacitidine + entinostat + nivolumab.

Explore the full profile